{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["146(19)"],"submitter":["Stelljes M"],"pubmed_abstract":["<h4>Abstract</h4>Attempting to induce a complete remission before allogeneic hematopoietic cell transplant (alloHCT) is current practice in patients with acute myeloid leukemia (AML). However, benefit of remission induction strategy (RIST) before alloHCT has never been proven in a prospective trial. Potent conditioning regimens exist that allow for successful alloHCT in patients with active AML. Therefore, the ASAP trial was conducted to test RIST by salvage chemotherapy before alloHCT against immediate transplant after intensified conditioning. In total, 281 patients with AML with poor response after first induction or untreated first relapse were randomized 1:1 to RIST with high-dose cytarabine plus mitoxantrone vs immediate alloHCT with sequential conditioning after nonintensive disease"],"journal":["Blood"],"pagination":["2293-2305"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12824691"],"repository":["biostudies-literature"],"pubmed_title":["Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial."],"pmcid":["PMC12824691"],"pubmed_authors":["Schmid C","Trost S","Schmidt AH","Klein SA","Lang F","Wagner-Drouet EM","Hauptrock B","Bethge W","Ehninger G","Reicherts C","Berdel WE","Stolzel F","Kriege O","Stelljes M","Schafer-Eckart K","Egger-Heidrich K","Kunadt D","Schaffrath J","Muller LP","Bug G","Platzbecker U","Steffen B","Mikesch JH","Niederland J","Schetelig J","Kaufmann M","Baldauf H","Serve H","Sockel K","Bornhauser M","Krause SW","Jost E","Middeke JM","Rollig C","von Bonin M","Schliemann C"],"additional_accession":[]},"is_claimable":false,"name":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.","description":"<h4>Abstract</h4>Attempting to induce a complete remission before allogeneic hematopoietic cell transplant (alloHCT) is current practice in patients with acute myeloid leukemia (AML). However, benefit of remission induction strategy (RIST) before alloHCT has never been proven in a prospective trial. Potent conditioning regimens exist that allow for successful alloHCT in patients with active AML. Therefore, the ASAP trial was conducted to test RIST by salvage chemotherapy before alloHCT against immediate transplant after intensified conditioning. In total, 281 patients with AML with poor response after first induction or untreated first relapse were randomized 1:1 to RIST with high-dose cytarabine plus mitoxantrone vs immediate alloHCT with sequential conditioning after nonintensive disease","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-13T05:05:44.587Z","creation":"2026-06-13T03:09:15.672Z"},"accession":"S-EPMC12824691","cross_references":{"pubmed":["40737595"],"doi":["10.1182/blood.2025028730"]}}